160 related articles for article (PubMed ID: 20657554)
1. Immunohistochemical detection of ZAP70 in chronic lymphocytic leukemia predicts immunoglobulin heavy chain gene mutation status and time to progression.
Admirand JH; Knoblock RJ; Coombes KR; Tam C; Schlette EJ; Wierda WG; Ferrajoli A; O'Brien S; Keating MJ; Luthra R; Medeiros LJ; Abruzzo LV
Mod Pathol; 2010 Nov; 23(11):1518-23. PubMed ID: 20657554
[TBL] [Abstract][Full Text] [Related]
2. Quantification of ZAP70 mRNA in B cells by real-time PCR is a powerful prognostic factor in chronic lymphocytic leukemia.
Stamatopoulos B; Meuleman N; Haibe-Kains B; Duvillier H; Massy M; Martiat P; Bron D; Lagneaux L
Clin Chem; 2007 Oct; 53(10):1757-66. PubMed ID: 17702857
[TBL] [Abstract][Full Text] [Related]
3. High expression of lymphocyte-activation gene 3 (LAG3) in chronic lymphocytic leukemia cells is associated with unmutated immunoglobulin variable heavy chain region (IGHV) gene and reduced treatment-free survival.
Kotaskova J; Tichy B; Trbusek M; Francova HS; Kabathova J; Malcikova J; Doubek M; Brychtova Y; Mayer J; Pospisilova S
J Mol Diagn; 2010 May; 12(3):328-34. PubMed ID: 20228263
[TBL] [Abstract][Full Text] [Related]
4. Quantification of ZAP-70 mRNA by real-time PCR is a prognostic factor in chronic lymphocytic leukemia.
Wang YH; Zou ZJ; Liu L; Zhang LN; Fang C; Zhu DX; Fan L; Li JY; Xu W
J Cancer Res Clin Oncol; 2012 Jun; 138(6):1011-7. PubMed ID: 22362302
[TBL] [Abstract][Full Text] [Related]
5. COBLL1, LPL and ZAP70 expression defines prognostic subgroups of chronic lymphocytic leukemia patients with high accuracy and correlates with IGHV mutational status.
Plesingerova H; Librova Z; Plevova K; Libra A; Tichy B; Skuhrova Francova H; Vrbacky F; Smolej L; Mayer J; Bryja V; Doubek M; Pospisilova S
Leuk Lymphoma; 2017 Jan; 58(1):70-79. PubMed ID: 27185377
[TBL] [Abstract][Full Text] [Related]
6. ZAP70 in B-CLL cells related to the expression in NK cells is a surrogate marker for mutational status.
Wiggers TG; Westra G; Westers TM; Abbes AP; Strunk A; Kuiper-Kramer E; Poddighe P; van de Loosdrecht AA; Chamuleau ME
Cytometry B Clin Cytom; 2014 Jul; 86(4):280-7. PubMed ID: 24924909
[TBL] [Abstract][Full Text] [Related]
7. Gene expression profiling reveals differences in microenvironment interaction between patients with chronic lymphocytic leukemia expressing high versus low ZAP70 mRNA.
Stamatopoulos B; Haibe-Kains B; Equeter C; Meuleman N; Sorée A; De Bruyn C; Hanosset D; Bron D; Martiat P; Lagneaux L
Haematologica; 2009 Jun; 94(6):790-9. PubMed ID: 19377082
[TBL] [Abstract][Full Text] [Related]
8. Surrogate molecular markers for IGHV mutational status in chronic lymphocytic leukemia for predicting time to first treatment.
Morabito F; Cutrona G; Mosca L; D'Anca M; Matis S; Gentile M; Vigna E; Colombo M; Recchia AG; Bossio S; De Stefano L; Maura F; Manzoni M; Ilariucci F; Consoli U; Vincelli I; Musolino C; Cortelezzi A; Molica S; Ferrarini M; Neri A
Leuk Res; 2015 Aug; 39(8):840-5. PubMed ID: 26038121
[TBL] [Abstract][Full Text] [Related]
9. Comparison of ZAP-70/Syk mRNA levels with immunoglobulin heavy-chain gene mutation status and disease progression in chronic lymphocytic leukemia.
Laurenti L; Petlickovski A; Rumi C; Gobessi S; Piccioni P; Tarnani M; Puggioni P; Marietti S; Sica S; Leone G; Efremov DG
Haematologica; 2005 Nov; 90(11):1533-40. PubMed ID: 16266901
[TBL] [Abstract][Full Text] [Related]
10. Lipoprotein lipase mRNA expression in whole blood is a prognostic marker in B cell chronic lymphocytic leukemia.
Van Bockstaele F; Pede V; Janssens A; Callewaert F; Offner F; Verhasselt B; Philippé J
Clin Chem; 2007 Feb; 53(2):204-12. PubMed ID: 17158192
[TBL] [Abstract][Full Text] [Related]
11. Clinical characteristics, response to therapy, and survival of African American patients diagnosed with chronic lymphocytic leukemia: joint experience of the MD Anderson Cancer Center and Duke University Medical Center.
Falchi L; Keating MJ; Wang X; Coombs CC; Lanasa MC; Strom S; Wierda WG; Ferrajoli A
Cancer; 2013 Sep; 119(17):3177-85. PubMed ID: 24022787
[TBL] [Abstract][Full Text] [Related]
12. ZAP70 expression assessed by immunohistochemistry on peripheral blood: a simple prognostic assay for patients with chronic lymphocytic leukemia.
Roullet M; Sargent R; Pasha T; Cajiao I; Elstrom R; Smith T; Liebhaber S; Zhang P; Bagg A
Appl Immunohistochem Mol Morphol; 2007 Dec; 15(4):471-6. PubMed ID: 18091393
[TBL] [Abstract][Full Text] [Related]
13. Most morphologic features in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) do not reliably predict underlying FISH genetics or immunoglobulin heavy chain variable region somatic mutational status.
Garcia CF; Hunt KE; Kang H; Babb A; Gale JM; Vasef MA; Reichard KK
Appl Immunohistochem Mol Morphol; 2010 Mar; 18(2):119-27. PubMed ID: 19826250
[TBL] [Abstract][Full Text] [Related]
14. Bone marrow infiltration pattern in B-cell chronic lymphocytic leukemia is related to immunoglobulin heavy-chain variable region mutation status and expression of 70-kd zeta-associated protein (ZAP-70).
Schade U; Bock O; Vornhusen S; Jäger A; Büsche G; Lehmann U; Kreipe H
Hum Pathol; 2006 Sep; 37(9):1153-61. PubMed ID: 16938520
[TBL] [Abstract][Full Text] [Related]
15. B cell chronic lymphocytic leukaemia/small lymphocytic lymphoma: role of ZAP70 determination on bone marrow biopsy specimens.
Sabattini E; Orduz R; Campidelli C; Zinzani PL; Callea V; Zupo S; Cutrona G; Morabito F; Ferrarini M; Pileri S
J Clin Pathol; 2007 Jun; 60(6):627-32. PubMed ID: 16916999
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of ZAP-70 expression in chronic lymphocytic leukemia as assessed by quantitative polymerase chain reaction and flow cytometry.
Adams RL; Cheung C; Banh R; Saal R; Cross D; Gill D; Self M; Klein K; Mollee P
Cytometry B Clin Cytom; 2014 Mar; 86(2):80-90. PubMed ID: 24127306
[TBL] [Abstract][Full Text] [Related]
17. Detection methods of ZAP-70 in chronic lymphocytic leukemia.
Wang YH; Fan L; Xu W; Li JY
Clin Exp Med; 2012 Jun; 12(2):69-77. PubMed ID: 21691729
[TBL] [Abstract][Full Text] [Related]
18. Validation of ZAP-70 methylation and its relative significance in predicting outcome in chronic lymphocytic leukemia.
Claus R; Lucas DM; Ruppert AS; Williams KE; Weng D; Patterson K; Zucknick M; Oakes CC; Rassenti LZ; Greaves AW; Geyer S; Wierda WG; Brown JR; Gribben JG; Barrientos JC; Rai KR; Kay NE; Kipps TJ; Shields P; Zhao W; Grever MR; Plass C; Byrd JC
Blood; 2014 Jul; 124(1):42-8. PubMed ID: 24868078
[TBL] [Abstract][Full Text] [Related]
19. Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia.
Wierda WG; O'Brien S; Wang X; Faderl S; Ferrajoli A; Do KA; Garcia-Manero G; Cortes J; Thomas D; Koller CA; Burger JA; Lerner S; Schlette E; Abruzzo L; Kantarjian HM; Keating MJ
J Clin Oncol; 2011 Nov; 29(31):4088-95. PubMed ID: 21969505
[TBL] [Abstract][Full Text] [Related]
20. FCRL2 expression predicts IGHV mutation status and clinical progression in chronic lymphocytic leukemia.
Li FJ; Ding S; Pan J; Shakhmatov MA; Kashentseva E; Wu J; Li Y; Soong SJ; Chiorazzi N; Davis RS
Blood; 2008 Jul; 112(1):179-87. PubMed ID: 18314442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
